DiaMedica Therapeutics (DMAC) Competitors $4.57 -0.38 (-7.68%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$4.57 0.00 (-0.11%) As of 03/25/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. NTLA, ELVN, BGM, RCUS, VIR, COLL, RCKT, XNCR, REPL, and PAHCShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Intellia Therapeutics (NTLA), Enliven Therapeutics (ELVN), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Replimune Group (REPL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Intellia Therapeutics Enliven Therapeutics Qilian International Holding Group Arcus Biosciences Vir Biotechnology Collegium Pharmaceutical Rocket Pharmaceuticals Xencor Replimune Group Phibro Animal Health DiaMedica Therapeutics (NASDAQ:DMAC) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends. Do institutionals & insiders believe in DMAC or NTLA? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 7.2% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor DMAC or NTLA? Intellia Therapeutics received 349 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 68.90% of users gave Intellia Therapeutics an outperform vote while only 63.09% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% Intellia TherapeuticsOutperform Votes44368.90% Underperform Votes20031.10% Is DMAC or NTLA more profitable? DiaMedica Therapeutics' return on equity of -43.67% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% Intellia Therapeutics N/A -49.34%-40.27% Which has better earnings & valuation, DMAC or NTLA? DiaMedica Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.60-7.62Intellia Therapeutics$57.88M15.61-$481.19M-$5.25-1.66 Does the media favor DMAC or NTLA? In the previous week, Intellia Therapeutics had 27 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 37 mentions for Intellia Therapeutics and 10 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.58 beat Intellia Therapeutics' score of 0.24 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 8 Very Positive mention(s) 4 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, DMAC or NTLA? DiaMedica Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Do analysts rate DMAC or NTLA? DiaMedica Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 75.05%. Intellia Therapeutics has a consensus target price of $37.56, indicating a potential upside of 330.19%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63 SummaryIntellia Therapeutics beats DiaMedica Therapeutics on 11 of the 17 factors compared between the two stocks. Remove Ads Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.85M$6.99B$5.68B$8.30BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-8.167.2324.5819.25Price / SalesN/A232.30388.0794.32Price / CashN/A65.6738.1634.64Price / Book3.396.617.084.46Net Income-$19.38M$142.13M$3.19B$247.07M7 Day Performance-12.79%-1.51%-0.94%0.14%1 Month Performance-26.88%-3.46%3.55%-4.39%1 Year Performance68.01%-5.32%14.29%4.85% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.6235 of 5 stars$4.57-7.7%$8.00+75.1%+70.5%$195.85MN/A-8.1620High Trading VolumeNTLAIntellia Therapeutics4.4718 of 5 stars$9.82+7.4%$37.56+282.6%-67.5%$1.02B$57.88M-1.80600Analyst RevisionELVNEnliven Therapeutics2.8775 of 5 stars$20.730.0%$38.25+84.5%+19.9%$1.01BN/A-10.9250BGMQilian International Holding GroupN/A$10.06+4.7%N/AN/A$977.57M$25.10M0.00298RCUSArcus Biosciences2.3158 of 5 stars$9.26-0.9%$30.25+226.7%-49.1%$973.58M$258M-2.94500VIRVir Biotechnology3.7586 of 5 stars$7.05-1.3%$35.67+405.6%-30.5%$967.54M$63.71M-1.80580Positive NewsCOLLCollegium Pharmaceutical4.0272 of 5 stars$29.74+1.0%$43.60+46.6%-24.9%$936.39M$631.45M12.82210Analyst ForecastAnalyst RevisionRCKTRocket Pharmaceuticals4.7764 of 5 stars$8.72-0.4%$43.00+393.0%-69.6%$931.41MN/A-3.18240Positive NewsXNCRXencor3.3791 of 5 stars$13.10+2.7%$34.38+162.4%-46.0%$923.05M$110.49M-4.09280REPLReplimune Group3.8306 of 5 stars$11.81+1.3%$19.43+64.5%+32.8%$909.62MN/A-3.85210Positive NewsPAHCPhibro Animal Health3.2432 of 5 stars$21.87+2.9%$21.00-4.0%+71.4%$885.76M$1.11B45.561,860Analyst DowngradePositive News Remove Ads Related Companies and Tools Related Companies Intellia Therapeutics Alternatives Enliven Therapeutics Alternatives Qilian International Holding Group Alternatives Arcus Biosciences Alternatives Vir Biotechnology Alternatives Collegium Pharmaceutical Alternatives Rocket Pharmaceuticals Alternatives Xencor Alternatives Replimune Group Alternatives Phibro Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
